MobCon: The Comorbidity of Benign Hypermobility Joint Syndrome and Functional Constipation in Children

Sponsor
Medical University of Warsaw (Other)
Overall Status
Unknown status
CT.gov ID
NCT02854098
Collaborator
(none)
400
1
30
13.3

Study Details

Study Description

Brief Summary

Benign Hypermobility Joint Syndrome is a group of inherited abnormalities in the structure of connective tissues, manifested by disturbances in the proportion of collagen. The main symptoms of this syndrome include: laxity of joint capsules and ligaments, hypermobility of the joints, as well as numerous disturbances in the functioning of internal organs that contain connective tissue, including the gastrointestinal tract. Hypermobility of joints affects approximately 10% of the population of Western countries, is more common in small children and female. Modified Beighton scale is the basic scale for assessing hypermobility of joints. The scale (as assessed using the goniometer) is a reliable tool for the evaluation of excessive laxity of the connective tissue in children.

Functional constipation is a very common condition, affecting approximately 3-5% of children and adolescents, with peak onset between 2 and 4 years of age. The etiology of this disorder is multifactorial, and till day it is still exactly unknown why some children develop constipation, while in others we can observe the correct scheme of defecation. Suspending stool enhances the retention of fecal masses, which subsequently causes painful defecation. Diagnosis is based on history, clinical symptoms and physical examination. Increased susceptibility of the wall of the distal gastrointestinal tract could explain the predisposition of some children to retain fecal masses and the development of constipation.

Due to the unclear etiology of functional constipation, it seems reasonable to conduct a study assessing whether excessive laxity of connective tissue (assessed on the basis of the hypermobility of the joints) facilitates the accumulation of stool in the large intestine, and so is the one of the reasons leading to development of functional constipation in children.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Clinical question: Is there among patients with functional constipation increased percentage of children with Benign Hypermobility Joint Syndrome, compared with a population of healthy children? In discussion we would like to determine whether the excessive laxity of connective tissue can promote the development of functional constipation in children.

    Description of the study:
    1. Anamnesis and physical examination of the patient

    2. The consent of the parents and the patient (if > 15 years) to participate in the study

    3. Determining whether the patient meets the criteria for inclusion in the study

    4. The exclusion of patients meeting the exclusion criteria for the study - on the basis of anamnesis and physical examination (including neurological) and diagnostic tests (biochemical and electrolyte TSH -, Na, K, Ca, P, Mg), if indicated

    5. In patients classified to the study, the degree of laxity of the connective tissue will be assessed in the basis of modified Beighton scale

    6. In the control group - patients without constipation in an interview - the degree of laxity of the connective tissue will be assessed in the basis of modified Beighton scale

    7. Evaluation of the results.

    Rome III Criteria Functional Constipation

    Diagnostic criteria must include one month in children up to 4 years of age and two months in older children(with insufficient criteria for diagnosis of IBS) of at least two of the following:

    1. Two or fewer defecations per week

    2. At least one episode/week of incontinence after the acquisition of toileting skills

    3. History of excessive stool retention

    4. History of painful or hard bowel movements

    5. Presence of a large fecal mass in the rectum

    6. History of large diameter stools which may obstruct the toilet Accompanying symptoms may include irritability, decreased appetite, and/or early satiety. The accompanying symptoms disappear immediately following passage of a large stool.

    Modified Beighton scale Hypermobility of joints indicates ≥ 4 points out of 9 possible.

    The Beighton score is measured by adding 1 point for each of the following:
    1. Placing flat hands on the floor with straight legs

    2. Left knee bending backward (>10 °)

    3. Right knee bending backward (>10 °)

    4. Left elbow bending backward (>10 °)

    5. Right elbow bending backward (>10 °)

    6. Left thumb touching the forearm

    7. Right thumb touching the forearm

    8. Left little finger bending backward (>90 °)

    9. Right little finger bending backward (>90 °)

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    400 participants
    Observational Model:
    Other
    Time Perspective:
    Cross-Sectional
    Official Title:
    The Comorbidity of Benign Hypermobility Joint Syndrome and Functional Constipation in Children
    Study Start Date :
    Apr 1, 2015
    Anticipated Primary Completion Date :
    Jun 1, 2017
    Anticipated Study Completion Date :
    Oct 1, 2017

    Arms and Interventions

    Arm Intervention/Treatment
    with functional constipation

    n = 200 patients with functional constipation examined for BHJS age 3 -18 years meet inclusion criteria, do not fulfill exclusion criteria

    without functional constipation

    n = 200 patient with functional constipation examined for BHJS age 3 -18 years meet inclusion criteria, do not fulfill exclusion criteria

    Outcome Measures

    Primary Outcome Measures

    1. The comorbidity of benign hypermobility joint syndrome and functional constipation in children (in %) [April 2017]

      The Hypermobility of the connective tissue as one of the etiological factors of functional constipation in children

    Secondary Outcome Measures

    1. The comorbidity of BHJS and functional constipation, depending on age (in %) [April 2017]

    2. The comorbidity of BHJS and functional constipation, depending on gender (in %) [April 2017]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    3 Years to 18 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    First group:
    Inclusion Criteria:
    1. Age 3 - 18 years.

    2. Diagnosed functional constipation (on the basis of III Rome Criteria)

    3. Informed consent of patients (if more than 16 years) and caregivers

    Exclusion Criteria:
    1. Organic causes of constipation (anatomical abnormalities: narrowing of the anus or rectum, state after surgical correction of this anomalies)

    2. Metabolic and gastrological diseases in anamnesis: hypothyroidism, hypercalcemia, hypokalemia, cystic fibrosis, diabetes, celiac disease

    3. Neuropathies: defects and injures of the spinal cord, encephalopathies

    4. Neuromuscular disorders: Hirschsprung's disease, intestinal neuronal dysplasia, visceral myopathies and neuropathies

    5. Abnormal abdominal musculature: Down syndrome;

    6. The use of drugs (opioids, phenobarbital, sucralfate, antidepressants, anticholinergic, sympathomimetic)

    7. Lack of informed consent of patients (if more than 16 years) and caregivers

    Second group:
    Inclusion Criteria:
    1. Age 3 - 18 years.

    2. Without functional constipation

    3. Informed consent of patients and caregivers

    Exclusion Criteria:

    1 Lack of informed consent of patients and caregivers

    Place: Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, Poland

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw Warsaw Mazowieckie Poland 02-091

    Sponsors and Collaborators

    • Medical University of Warsaw

    Investigators

    • Study Chair: Piotr Albrecht, PhD, Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Andrzej Załęski, M.D., Medical University of Warsaw
    ClinicalTrials.gov Identifier:
    NCT02854098
    Other Study ID Numbers:
    • 1W33
    First Posted:
    Aug 3, 2016
    Last Update Posted:
    Mar 31, 2017
    Last Verified:
    Mar 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by Andrzej Załęski, M.D., Medical University of Warsaw
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 31, 2017